Condition category
Not Applicable
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
There is an urgent need to ensure that medicines given to children are assessed sufficiently. A range of methods have been proposed to do this. The aim of the study is to apply and test a method called microtracer dosing with accelerator mass spectrometry (AMS) bioanalysis, using paracetamol as a model drug and find out its effects on newborn, infants and toddlers. The results are compared with the information available in previous research that used standard methods. This study could establish a way for AMS studies to be a part of Paediatric Investigation Plans for development of new drugs. This will mean that new drugs can be given to children earlier than in current practice.

Who can participate?
Male and female hospitalised infants aged between preterm up to 2 years can participate in this study.

What does the study involve?
A single microdose of radioactive paracetamol will be given to infants whose age range is preterm up to 2 years of age orally or injected through the vein. A maximum of 20 extra drops of blood is taken from each participant. This is spread over the 12 hours after the isotope dose is received. The total amount of blood taken will be 1ml. The blood is taken via the lines already in place. The maximum length of participation in the study is up to 48 hours after giving the study drug.

What are the possible benefits and risks of participating?
The participants will not gain any direct benefit. The benefits from this study are for other babies in the future as the information gathered in this study becomes available. The risks due to paracetamol will be minimal as this microdose is less than a millionth of the dose normally given to newborn babies and infants. There are no anticipated safety issues relating to exposure to the radioactive drug.

Where is the study run from?
The study is run from the following sites:
1. Liverpool Women’s NHS Foundation Trust, UK (lead centre)
2. Tartu University Hospital, Children’s Clinic, Estonia
3. Alder Hey Children’s NHS Foundation Trust, UK

When is the study starting and how long is it expected to run for?
The study started in November 2012 and will run for 2 years.

Who is funding the study?
ERA-NET PrioMedChild (Priority Medicines for Children), Netherlands.

Who is the main contact?
Miss Louise Hardman

Trial website

Contact information



Primary contact

Dr Mark Turner


Contact details

Liverpool Women's NHS Foundation Trust
Crown Street
L8 7SS
United Kingdom
+44 (0)151 795 9558

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

A multi-centre clinical study to evaluate the use of a microtrace dose of 14C-labelled paracetamol and Accelerator Mass Spectrometry (AMS) bioanalysis as new tools in drug development to determine pharmacokinetics in neonates, infants and toddlers



Study hypothesis

14C-labelled microdose paracetamol has similar PK to standard, therapeutic paracetamol

Ethics approval

NRES Committee North West - Liverpool East, 08 October 2012, ref: 12/NW/0675

Study design

A multicentre observational open label study

Primary study design


Secondary study design

Non randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Medicines for Children; Paediatrics


No specific study related assessments will be conducted.

No haematology, biochemistry or blood gas studies samples will be taken for the purposes of this study. The most recent blood samples will be included in the data if they are taken 24 hours before the drug is administered in neonates and up to 3-7 days before for older infants. A maximum of 5 blood samples after drug administration will also be collected. Details of blood results that will be collected for the study data are:

Biochemistry: Plasma creatinine, Na+, K+ Cl, AST, ALT, alkaline phosphatase, total bilirubin, conjugated bilirubin, albumin, total calcium, corrected calcium, magnesium, Creactive protein.
Full Blood Count: Hgb, total white cell count, differential white cell count, MCV, MCH, MCHC and platelets.
Blood gas: pH, glucose, lactate, ionized calcium

In participants with urinary catheters in place the urine collection bag will be emptied immediately before the microdose is administered. Timed samples of urine will be collected for 48 hours after the microdose is administered.

Intervention type



Not Applicable

Drug names

Primary outcome measures

A noncompartmental model of paracetamol disposition.

Secondary outcome measures

A population model of the whole dataset taking account of all the variables.

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Infants and toddlers from preterm neonates (32-36 GW at birth) up to 2 years of age
2. Having intravenous or intra-arterial access suitable for blood sampling
3. Written informed consent prior to any study-specific procedures
4. Able to tolerate oral administration for oral administration group

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. History of allergy or hypersensitivity to paracetamol;
2. Serious hepatic and/or renal impairment defined as creatinine > 150 micromol or AST or ALT > 200
3. Be otherwise unsuitable for the study, in the opinion of the investigator
4. Extracorporeal membrane oxygenation (ECMO)
5. Haemofiltration, peritoneal dialysis, haemodialysis

Recruitment start date


Recruitment end date



Countries of recruitment

Estonia, United Kingdom

Trial participating centre

Liverpool Women's NHS Foundation Trust
L8 7SS
United Kingdom

Sponsor information


Liverpool Women's NHS Foundation Trust (UK)

Sponsor details

Crown Street
L8 7SS
United Kingdom
+44 (0)151 702 4346

Sponsor type

Hospital/treatment centre



Funder type

Research organisation

Funder name

ERA-NET PrioMedChild (Priority Medicines for Children) (Netherlands)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes